Basic Information
RNALocate ID: | RLID:11001575 |
RNA Symbol: | hsa-miR-200b-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-200b |
RNA ID: | miRBase:MIMAT0000318 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001685 | Cytoplasm | Colon cancer cells | 20864815 |
RLID:01001686 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:11001571 | Exosome | Urine | 26576778 |
RLID:11001572 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001573 | Exosome | Brain tissue | 23382797 |
RLID:11001574 | Exosome | Plasma | 23663360 |
RLID-D:11000067 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
RLID-D:11000341 | Microvesicle | Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-200b-3p | Splenic marginal zone lymphoma | MNDR-E-MI-26092 |
MNDR | hsa-miR-200b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26093 |
MNDR | hsa-miR-200b-3p | Tongue squamous cell carcinoma | MNDR-E-MI-26094 |
MNDR | hsa-miR-200b-3p | Oral squamous cell carcinoma | MNDR-E-MI-26095 |
MNDR | hsa-miR-200b-3p | Large cell neuroendocrine cancer | MNDR-E-MI-26096 |
MNDR | hsa-miR-200b-3p | Medulloblastoma | MNDR-E-MI-26097 |
MNDR | hsa-miR-200b-3p | Mucosa-associated lymphoid tissue lymphoma | MNDR-E-MI-26098 |
MNDR | hsa-miR-200b-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26099 |
MNDR | hsa-miR-200b-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26100 |
MNDR | hsa-miR-200b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26101 |
MNDR | hsa-miR-200b-3p | Lymphoma non-hodgkin | MNDR-E-MI-26102 |
MNDR | hsa-miR-200b-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26103 |
MNDR | hsa-miR-200b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26104 |
MNDR | hsa-miR-200b-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26105 |
MNDR | hsa-miR-200b-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26106 |
MNDR | hsa-miR-200b-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26107 |
MNDR | hsa-miR-200b-3p | Triple negative breast cancer | MNDR-E-MI-26108 |
MNDR | hsa-miR-200b-3p | Breast cancer luminal | MNDR-E-MI-26109 |
MNDR | hsa-miR-200b-3p | Androgen-independent prostate cancer | MNDR-E-MI-26110 |
MNDR | hsa-miR-200b-3p | Gastric cancer | MNDR-E-MI-26111 |
MNDR | hsa-miR-200b-3p | Gastric lymphoma | MNDR-E-MI-26112 |
MNDR | hsa-miR-200b-3p | Alzheimer disease | MNDR-E-MI-26113 |
MNDR | hsa-miR-200b-3p | Bladder cancer | MNDR-E-MI-26114 |
MNDR | hsa-miR-200b-3p | Head and neck cancer | MNDR-E-MI-26115 |
MNDR | hsa-miR-200b-3p | Ataxia telangiectasia | MNDR-E-MI-26116 |
MNDR | hsa-miR-200b-3p | Cardiovascular disease | MNDR-E-MI-26117 |
MNDR | hsa-miR-200b-3p | Lung cancer | MNDR-E-MI-26118 |
MNDR | hsa-miR-200b-3p | Endometrial cancer | MNDR-E-MI-26119 |
MNDR | hsa-miR-200b-3p | Parkinson disease | MNDR-E-MI-26120 |
MNDR | hsa-miR-200b-3p | Basal-like breast cancer | MNDR-E-MI-26121 |
MNDR | hsa-miR-200b-3p | Cancer | MNDR-E-MI-26122 |
MNDR | hsa-miR-200b-3p | Thyroid cancer | MNDR-E-MI-26123 |
MNDR | hsa-miR-200b-3p | Pituitary neoplasms | MNDR-E-MI-26124 |
MNDR | hsa-miR-200b-3p | Pancreatic cancer | MNDR-E-MI-26125 |
MNDR | hsa-miR-200b-3p | Melanoma | MNDR-E-MI-26126 |
MNDR | hsa-miR-200b-3p | Rectum adenocarcinoma | MNDR-E-MI-26127 |
MNDR | hsa-miR-200b-3p | Nephroblastoma | MNDR-E-MI-26128 |
MNDR | hsa-miR-200b-3p | Colon cancer | MNDR-E-MI-26129 |
MNDR | hsa-miR-200b-3p | Ischemic attack transient | MNDR-E-MI-26130 |
MNDR | hsa-miR-200b-3p | Colon adenocarcinoma | MNDR-E-MI-26131 |
MNDR | hsa-miR-200b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26132 |
MNDR | hsa-miR-200b-3p | Familial ovarian cancer | MNDR-E-MI-26133 |
MNDR | hsa-miR-200b-3p | Acromegaly | MNDR-E-MI-26134 |
MNDR | hsa-miR-200b-3p | Kidney cancer | MNDR-E-MI-26135 |
MNDR | hsa-miR-200b-3p | Endometrial adenocarcinoma | MNDR-E-MI-26136 |
MNDR | hsa-miR-200b-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-26137 |
MNDR | hsa-miR-200b-3p | Endometriosis | MNDR-E-MI-26138 |
MNDR | hsa-miR-200b-3p | Carcinoma ductal breast | MNDR-E-MI-26139 |
MNDR | hsa-miR-200b-3p | Glioblastoma | MNDR-E-MI-26140 |
MNDR | hsa-miR-200b-3p | Astrocytoma | MNDR-E-MI-26141 |
MNDR | hsa-miR-200b-3p | Glioma | MNDR-E-MI-26142 |
MNDR | hsa-miR-200b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-26143 |
MNDR | hsa-miR-200b-3p | Breast carcinoma | MNDR-E-MI-26144 |
MNDR | hsa-miR-200b-3p | Uterine cancer | MNDR-E-MI-26145 |
MNDR | hsa-miR-200b-3p | Cervical adenocarcinoma | MNDR-E-MI-26146 |
MNDR | hsa-miR-200b-3p | Gastric adenocarcinoma | MNDR-E-MI-26147 |
MNDR | hsa-miR-200b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26148 |
MNDR | hsa-miR-200b-3p | Pituitary adenoma | MNDR-E-MI-26149 |
MNDR | hsa-miR-200b-3p | Lung squamous cell carcinoma | MNDR-E-MI-26150 |
MNDR | hsa-miR-200b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-26151 |
MNDR | hsa-miR-200b-3p | Lung adenocarcinoma | MNDR-E-MI-26152 |
MNDR | hsa-miR-200b-3p | Ovarian carcinoma | MNDR-E-MI-26153 |
MNDR | hsa-miR-200b-3p | Bladder urothelial carcinoma | MNDR-E-MI-26154 |
MNDR | hsa-miR-200b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-26155 |
MNDR | hsa-miR-200b-3p | Carcinoma renal cell | MNDR-E-MI-26156 |
MNDR | hsa-miR-200b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26157 |
MNDR | hsa-miR-200b-3p | Clear cell renal cell carcinoma | MNDR-E-MI-26158 |
MNDR | hsa-miR-200b-3p | Allergic rhinitis | MNDR-E-MI-26159 |
MNDR | hsa-miR-200b-3p | Biliary tract cancer | MNDR-E-MI-26160 |
MNDR | hsa-miR-200b-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-26161 |
MNDR | hsa-miR-200b-3p | Cholangiocarcinoma | MNDR-E-MI-26162 |
MNDR | hsa-miR-200b-3p | Lung small cell carcinoma | MNDR-E-MI-26163 |
MNDR | hsa-miR-200b-3p | Gastric carcinoma | MNDR-E-MI-26164 |
MNDR | hsa-miR-200b-3p | Testicular germ cell cancer | MNDR-E-MI-26165 |
MNDR | hsa-miR-200b-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-26166 |
MNDR | hsa-miR-200b-3p | Adenoma | MNDR-E-MI-26167 |
MNDR | hsa-miR-200b-3p | Breast invasive carcinoma | MNDR-E-MI-26168 |
MNDR | hsa-miR-200b-3p | Hepatocellular carcinoma | MNDR-E-MI-26169 |
MNDR | hsa-miR-200b-3p | Familiar ovarian carcinoma | MNDR-E-MI-26170 |
MNDR | hsa-miR-200b-3p | B-cell lymphoma | MNDR-E-MI-26171 |
MNDR | hsa-miR-200b-3p | Malignant pleural mesothelioma | MNDR-E-MI-26172 |
MNDR | hsa-miR-200b-3p | Periodontitis | MNDR-E-MI-26173 |
MNDR | hsa-miR-200b-3p | Hodgkin lymphoma | MNDR-E-MI-26174 |
MNDR | hsa-miR-200b-3p | Ulcerative colitis | MNDR-E-MI-26175 |
MNDR | hsa-miR-200b-3p | Burkitt lymphoma | MNDR-E-MI-26176 |
MNDR | hsa-miR-200b-3p | Crohn disease | MNDR-E-MI-26177 |
MNDR | hsa-miR-200b-3p | Skin cutaneous melanoma | MNDR-E-MI-26178 |
MNDR | hsa-miR-200b-3p | Skin melanoma | MNDR-E-MI-26179 |
MNDR | hsa-miR-200b-3p | Acute myelogenous leukemia | MNDR-E-MI-26180 |
MNDR | hsa-miR-200b-3p | Colorectal cancer | MNDR-E-MI-26181 |
MNDR | hsa-miR-200b-3p | Multiple myeloma | MNDR-E-MI-26182 |
MNDR | hsa-miR-200b-3p | Type 1 diabetes mellitus | MNDR-E-MI-26183 |
MNDR | hsa-miR-200b-3p | Ovarian epithelial cancer | MNDR-E-MI-26184 |
MNDR | hsa-miR-200b-3p | Autoimmune diseases | MNDR-E-MI-26185 |
MNDR | hsa-miR-200b-3p | Graft vs host disease | MNDR-E-MI-26186 |
MNDR | hsa-miR-200b-3p | Prostatic neoplasms | MNDR-E-MI-26187 |
MNDR | hsa-miR-200b-3p | Chronic pain | MNDR-E-MI-26188 |
MNDR | hsa-miR-200b-3p | Breast cancer her3+ negative | MNDR-E-MI-26189 |
MNDR | hsa-miR-200b-3p | Cholestatic liver injury | MNDR-E-MI-26190 |
MNDR | hsa-miR-200b-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-26191 |
MNDR | hsa-miR-200b-3p | Tubulovillous adenoma | MNDR-E-MI-26192 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADAM12 | Homo sapiens | RR00040359 |
TOP